In Brief: FDA reform
This article was originally published in The Tan Sheet
Executive Summary
FDA reform: At a May 12 briefing for House Commerce Committee staff, the Pharmaceutical Research & Manufacturers Association noted that one of its "14 points" for FDA reform is increased facilitation of Rx-to-OTC switches. The Biotechnology Industry Organization proposed that FDA consolidate its drug, medical device and biologics centers to create "consistent" regulation of finished products rather than processes...